Enhancement of Ovarian Malignancy on Clinical Contrast Enhanced MRI Studies
Table 2
Lesion/fat ratio enhancement. Enhancement characteristics of (lesion/fat) ratio stratified by type of ovarian pathology and reader.
Enhancement characteristics of lesion/fat ratio by ovarian pathology and reader.
Pathology
% (lesion/fat) enhancement
Reader 1
Reader 2
Mean (SD)
Median (range)
Mean (SD)
Median (range)
High grade serous carcinoma
Post 1
77.8 (88.1)
55.5 (2.6, 358.1)
106.4 (147.4)
63.1 (−1.7, 610.8)
Highest enhancement
160.1 (124.3)
102.1 (7.0, 433.1)
160.4 (142.4)
106.2 (34.7, 610.8)
Other epithelial carcinoma
Post 1
90.1 (63.3)
72.1 (11.3, 202.2)
82.8 (38.2)
76.7 (33.1, 151.3)
Highest enhancement
138.9 (88.9)
126.6 (23.2, 320.3)
216.4 (184.5)
178.4 (48.6, 698.6)
Other non-epithelial cancer
Post 1
67.4 (87.7)
45.3 (−27.4, 208.3)
83.6 (114.9)
45.0 (−8.1, 332.9)
Highest enhancement
129.3 (111.3)
90.0 (20.1, 363.9)
148.2 (80.8)
130.5 (63.3, 332.9)
Borderline tumor
Post 1
29.2 (27.5)
35.6 (−22.1, 61.1)
26.8 (23.5)
27.8 (0.0, 71.6)
Highest enhancement
92.5 (51.9)
82.0 (17.6, 180.3)
138.8 (117.2)
83.8 (0.0, 284.9)
Post 1: enhancement on first post contrast phase. Highest: highest enhancement demonstrated on all post contrast phases. Lesion/fat = ratio of lesion SI/fat SI on same phase. SI: signal intensity. % (Lesion/fat) enhancement = [(postcontrast lesion/fat SI − precontrast lesion/fat SI)/precontrast lesion/fat SI] × 100.
